Skip to main content
. 2021 Apr 15;12:652882. doi: 10.3389/fneur.2021.652882

Figure 6.

Figure 6

The CDKN2A/p16INK4a-CDK4-pRB signaling pathway is involved in the effect of TET2 on the cell cycle in PD cellular model. (A,C) The cells have been transfected with shRNA or NC for 24 h before different drug treatment. Proliferation inhibition rates was examined by the CCK-8 method. (B) Effects of TET2 inhibitor Bobcat339 on proliferation was detected by a CCK-8 assay. Bobcat339 (3 μM) was preincubated with cells for 12 h before MPP+ (2.5 mM) treatment. (D,E) SH-SY5Y cells were transfected with shTET2 or shNC for 24 h and then treated with RV (resveratrol 25 μM) (D,E), or EX-527(F,G) for 24 h then western blot was used to detect the protein level of p16 (p16INK4a). SH-SY5Y cells were treated with MPP+ (2.5 mM), RV (25 μM) separately for 24 h or were treated with RV for 12 h before MPP+ and then co-treated with MPP+ for 24 h. Western blot and quantification of protein was performed to detect p16 (H,I) CDK4, and pRb (J,K). (L,M) The SH-SY5Y cells have been transfected with shRNA or shNC for 24 h before MPP+ (2.5 mM) treatment. Western blot and quantification of protein was performed to detect apoptotic proteins. Data are shown as the mean ± SD (n = 3); *P < 0.05, **P < 0.01, ***P < 0.001.